stockportfolio.pro
Stocks / BEAM vs RLAY
BEAM vs RLAY
Beam Therapeutics Inc. and Relay Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Beam Therapeutics Inc. (BEAM) | Relay Therapeutics, Inc. (RLAY) | |
|---|---|---|
| Market cap | $3.0B | $3.1B |
| Revenue (latest FY) | $139.74M | $15.36M |
| Net income (latest FY) | $-79.99M | $-276.48M |
| Revenue growth (5y CAGR) | 466.3% | -28.6% |
| Net margin | -57.2% | -1800.6% |
| Return on equity | -6.5% | -48.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BEAM — free Open RLAY — freeFrequently asked questions
Which is bigger, BEAM or RLAY?
Relay Therapeutics, Inc. is larger by market capitalization — $3.1B versus $3.0B.
Which grows faster, BEAM or RLAY?
Over the last five fiscal years, Beam Therapeutics Inc. grew revenue faster — 466.3%/yr versus -28.6%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.